



REMISSION OR SUPER RESPONDER

SPECIAL TWO PART SERIES

Reference list for ADVENT Interactive Clinical Tutorial held on 10 August 2023

- Aletaha D, et al. Diagnosis and Management of Rheumatoid Arthritis: A Review. *JAMA*. 2018;320(13):1360-1372. [PMID: [30285183](#)]
- American Lung Association. Lung Cancer Key Findings. [Click to access](#). Accessed July 2023.
- Australian Government. Cancer Australia. Glossary. [Click to access](#). Accessed July 2023.
- Bai TR, et al. Severe exacerbations predict excess lung function decline in asthma. *Eur Respir J*. 2007;30(3):452-6. [PMID: [17537763](#)]
- Bateman ED, et al. Global Initiative for Asthma 2016-derived asthma control with fluticasone propionate and salmeterol: A Gaining Optimal Asthma Control (GOAL) study reanalysis. *Ann Allergy Asthma Immunol*. 2019;123(1):57-63.e2. [PMID: [31028894](#)]
- Bel EH, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. *N Engl J Med*. 2014;371(13):1189-97. [PMID: [25199060](#)]
- Bleecker ER, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β_2 -agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. *Lancet*. 2016;388(10056):2115-27. [PMID: [27609408](#)]
- Brannan J, Lougheed MD. Airway hyperresponsiveness in asthma: mechanisms, clinical significance, and treatment. *Front in Physiol*. 2012;3. [PMID: [23233839](#)]
- Busse WW, et al. Holy Grail: the journey towards disease modification in asthma. *Eur Respir Rev*. 2022; 31:210183. [PMID: [35197266](#)]
- Castro M, et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. *N Engl J Med*. 2018;378:2486–2496. [PMID: [29782217](#)]
- Couillard S, et al. Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide. *Thorax*. 2022;77:199–202. [PMID: [23233839](#)]
- Dutoit JJ, et al. Inhaled corticosteroids reduce the severity of bronchial hyperresponsiveness in asthma but oral theophylline does not. *Am Rev Respir Dis*. 1987;136(5):1174–1178. [PMID: [3674580](#)]
- Fahy JV. Type 2 inflammation in asthma-present in most, absent in many. *Nat Rev Immunol*. 2015;15:57–65. [PMID: [25534623](#)]
- Gandhi NA, et al. Targeting key proximal drivers of type 2 inflammation in disease. *Nat Rev Drug Discov*. 2016;15:35–50. [PMID: [26471366](#)]
- Gibson PG, et al. Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry. *Int Med J*. 2016;46(9):1054-62. [PMID: [27350385](#)]
- GINA. Global strategy for asthma management and prevention. 2023. [Click to access](#). Accessed March 2023.
- Green RH, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. *Lancet*. 2002;360(9347):1715-21. [PMID: [12480423](#)]
- Hanania NA, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. *Am J Respir Crit Care Med*. 2013;187(8):804-11. [PMID: [23471469](#)]
- Hanania NA, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. *Ann Intern Med*. 2011;154(9):573-82. [PMID: [21536936](#)]
- Humbert M, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. *Allergy*. 2005;60(3):309-16. [PMID: [15679715](#)]
- Kraft M, et al. Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma. *Eur Respir J*. 2021;58(6). [PMID: [34112734](#)]
- Laitinen LA, et al. A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. *J Allergy Clin Immunol*. 1992;90:32–42. [PMID: [1629507](#)]
- Lung Foundation Australia. The Next Breath. 2022. [Click to access](#). Accessed August 2023.
- Lung Foundation Australia. Making Lung Cancer A Fair Fight: A Blueprint for Reform 2018. [Click to access](#). Accessed August 2023
- Malinowski A, et al. Simultaneously increased fraction of exhaled nitric oxide levels and blood eosinophil counts relate to increased asthma morbidity. *J Allergy Clin Immunol*. 2016;138:1301–1308. e2. [PMID: [27113848](#)]
- Menzies-Gow A, et al. An expert consensus framework for asthma remission as a treatment goal. *J Allergy Clin Immunol*. 2020;145(3):757-765. [PMID: [31866436](#)]
- Menzies-Gow A, et al. Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab. *Adv Ther*. 2022;39(5):2065-84. [PMID: [35287231](#)]
- Meo C, et al. Spontaneous cancer remission after COVID-19: insights from the pandemic and their relevance for cancer treatment. *Journal of Translational Medicine* (2023) 21(1):273. [PMID: [37085802](#)]
- Nair P, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. *N Engl J Med*. 2017;376:2448-2458. [PMID: [25199060](#)]
- Nonaka M, et al. Combined stimulation with Poly(I:C), TNF-alpha and Th2 cytokines induces TARC production by human fibroblasts from the nose, bronchioles and lungs. *Int Arch Allergy Immunol*. 2010;152:327–341. [PMID: [20185925](#)]

32. Okyere DO, et al. Predictors of lung function trajectories in population-based studies: A systematic review. *Respirology*. 2021;26(10):938-59. [\[PMID: 34490723\]](#)
33. Ortega HG, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. *N Engl J Med*. 2014;371(13):1198-207. [\[PMID: 25199059\]](#)
34. Pavlidis S, et al. "T2-high" in severe asthma related to blood eosinophil, exhaled nitric oxide and serum periostin. *Eur Respir J*. 2019;53:1800938. [\[PMID: 30578390\]](#)
35. Pavord I, et al. Controversies in Allergy: Choosing a Biologic for Patients with Severe Asthma. *J Allergy Clin Immunol*. 2021;147(2):AB4. [\[PMID: 34958982\]](#)
36. Pavord ID, et al. Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma. *J Allergy Clin Immunol Pract*. 2022. Epub ahead of print: DOI: 10.1016/j.jaip.2022.11.043. [\[PMID: 36535524\]](#)
37. Pavord ID, et al. After asthma: redefining airways diseases. *Lancet* 2018; 391: 350–400. [\[PMID: 28911920\]](#)
38. Payne DNR, et al. Early thickening of the reticular basement membrane in children with difficult asthma. *Am J Respir Crit Care Med*. 2003;167(1):78-82. [\[PMID: 12502479\]](#)
39. Phelan PD, et al. The Melbourne Asthma Study: 1964-1999. *J Allergy Clin Immunol*. 2002;109(2):189-94. [\[PMID: 11842286\]](#)
40. Rabe KF, et al. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. *N Engl J Med*. 2018;378(26):2475-85. [\[PMID: 29782224\]](#)
41. Rastogi S, et al. P198 FeNo and blood eosinophils as biomarkers in predicting asthma exacerbations. *Thorax*. 2017;72:A190.1. [Click to access](#). Accessed July 2023.
42. Reddel HK, et al. Optimal asthma control, starting with high doses of inhaled budesonide. *Eur Respir J*. 2000;16:226–235. [\[PMID: 10968496\]](#)
43. Schneider JL, et al. ALK-positive lung cancer: a moving target. *Nat Cancer*. 2023;4(3):330-343. [\[PMID: 36797503\]](#)
44. Shaw DE, et al. Balancing the needs of the many and the few: where next for adult asthma guidelines? *Lancet Respir Med*. 2021;9:786–794. [\[PMID: 33639099\]](#)
45. Smolen JS, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. *Ann Rheum Dis*. 2023;82(1):3-18. [\[PMID: 36357155\]](#)
46. Sont JK, et al. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. *AJRCCM* 1999;159(4):1043-51. [\[PMID: 10194144\]](#)
47. The Cleveland Clinic. Remission in Cancer. [Click to access](#). Accessed July 2023
48. Thomas D, et al. Asthma remission: what is it and how can it be achieved? *Eur Respir J*. 2022; 3; 60(5):2102583. [\[PMID: 35361633\]](#)
49. Tsuge M, et al. Novel Lung Growth Strategy with Biological Therapy Targeting Airway Remodeling in Childhood Bronchial Asthma. *Children*. 2022. 9(8):1253. [Click to access](#). Accessed July 2023
50. Tupper OD, et al. Remission and Changes in Severity Over 30 Years in an Adult Asthma Cohort. *J Allergy Clin Immunol Pract*. 2021; 9(4):1595-1603.e5. [\[PMID: 33220516\]](#)
51. Wark PA, et al. Diagnosis and investigation in the severe asthma clinic. *Expert Rev Respir Med*. 2016;10(5):491-503. [\[PMID: 26967545\]](#)
52. Westerhof GA, et al. Clinical predictors of remission and persistence of adult-onset asthma. *J Allergy Clin Immunol*. 2018;141(1):104-9.e3. [\[PMID: 28438546\]](#)
53. Woodruff PG, et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. *Proc Natl Acad Sci U S A*. 2007;104(40):15858-15863. [\[PMID: 17898169\]](#)